These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 21737695)

  • 1. Beyond ipilimumab: new approaches target the immunological synapse.
    Garber K
    J Natl Cancer Inst; 2011 Jul; 103(14):1079-82. PubMed ID: 21737695
    [No Abstract]   [Full Text] [Related]  

  • 2. [New hope in metastatic melanoma treatment?].
    Guillot B
    Ann Dermatol Venereol; 2012 Oct; 139(10):693-4. PubMed ID: 23122388
    [No Abstract]   [Full Text] [Related]  

  • 3. Trial watch: ipilimumab success in melanoma provides boost for cancer immunotherapy.
    Nat Rev Drug Discov; 2010 Aug; 9(8):584. PubMed ID: 20671754
    [No Abstract]   [Full Text] [Related]  

  • 4. New approaches tackle rising pancreatic cancer rates.
    Brower V
    J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25535299
    [No Abstract]   [Full Text] [Related]  

  • 5. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
    Graziani G; Tentori L; Navarra P
    Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed death protein 1 inhibitors making inroads in multiple cancers.
    Brower V
    J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25957444
    [No Abstract]   [Full Text] [Related]  

  • 7. Cocktails for cancer with a measure of immunotherapy.
    Ledford H
    Nature; 2016 Apr; 532(7598):162-4. PubMed ID: 27075078
    [No Abstract]   [Full Text] [Related]  

  • 8. Ipilimumab in the treatment of metastatic melanoma: a summary of recent studies.
    Ascierto PA
    Tumori; 2013; 99(6):302e-5e. PubMed ID: 24503809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
    Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
    Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melanoma vaccines: possible progress after years of frustration?
    Schmidt C
    J Natl Cancer Inst; 2009 Feb; 101(3):140-1. PubMed ID: 19176461
    [No Abstract]   [Full Text] [Related]  

  • 11. Melanoma drug wins US approval.
    Ledford H
    Nature; 2011 Mar; 471(7340):561. PubMed ID: 21455150
    [No Abstract]   [Full Text] [Related]  

  • 12. American Association of Cancer Research Showcases Immunotherapy Advances.
    Brower V
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26243202
    [No Abstract]   [Full Text] [Related]  

  • 13. Second- and third-generation drugs for immuno-oncology treatment-The more the better?
    Dempke WCM; Fenchel K; Uciechowski P; Dale SP
    Eur J Cancer; 2017 Mar; 74():55-72. PubMed ID: 28335888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
    Hoos A; Ibrahim R; Korman A; Abdallah K; Berman D; Shahabi V; Chin K; Canetta R; Humphrey R
    Semin Oncol; 2010 Oct; 37(5):533-46. PubMed ID: 21074069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biology and clinical applications of CD40 in cancer treatment.
    Fonsatti E; Maio M; Altomonte M; Hersey P
    Semin Oncol; 2010 Oct; 37(5):517-23. PubMed ID: 21074067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer treatment: The killer within.
    Ledford H
    Nature; 2014 Apr; 508(7494):24-6. PubMed ID: 24695297
    [No Abstract]   [Full Text] [Related]  

  • 17. Update on the role of ipilimumab in melanoma and first data on new combination therapies.
    Maio M; Di Giacomo AM; Robert C; Eggermont AM
    Curr Opin Oncol; 2013 Mar; 25(2):166-72. PubMed ID: 23299197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunotherapy in the treatment of advanced or metastatic melanoma: nivolumab from phase I studies to approvement by European Medicines Agency].
    Queirolo P; Tanda ET
    Recenti Prog Med; 2015 Dec; 106(12):608-17. PubMed ID: 26780070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The immunological synapse as a pharmacological target.
    Finetti F; Baldari CT
    Pharmacol Res; 2018 Aug; 134():118-133. PubMed ID: 29898412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.
    Boasberg P; Hamid O; O'Day S
    Semin Oncol; 2010 Oct; 37(5):440-9. PubMed ID: 21074058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.